Alto Neuroscience, Inc. (ANRO): Total Assets
$184.69M
As of 2025-12-31
$254.07M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $184.69M | +4.0% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $177.54M | +104.9% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $86.63M | n/a | 2025-03-20, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $184.69M | +4.0% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $184.99M | -38.0% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $185.55M | +28.7% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $182.62M | +83.4% |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $192.35M | -12.7% |
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $193.44M | +74.4% |
| PepGen Inc. (PEPG) | 2025-12-31 | $173.91M | +15.3% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $172.25M | -45.4% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $198.10M | -30.2% |
Compare ANRO, LXRX, FBIO, BNTC side by side · Screen every company in Pharmaceutical Preparations ↗